Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis

Trial Profile

Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms VASCUVALDIC 2
  • Most Recent Events

    • 24 Mar 2017 New trial record
    • 10 Mar 2017 Status changed from recruiting to completed, according to results published in the Gastroenterology.
    • 10 Mar 2017 Results published in the Gastroenterology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top